Want to see CTNM full AI Analyst Report?
CTNM Stock Chart & Stats
$17.02
$0.22(1.56%)
At close: 4:00 PM EDT
$17.02
$0.22(1.56%)
Day’s Range― - ―
52-Week Range$6.73 - $17.79
Previous CloseN/A
Volume15.74K
Average Volume (3M)1.18M
Market Cap
$314.14M
Enterprise Value$384.12M
Total Cash (Recent Filing)$236.55M
Total Debt (Recent Filing)$6.57M
Price to Earnings (P/E)―
Beta0.32
Next Earnings
Nov 11, 2026EPS Estimate
-0.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.73
Shares Outstanding32,958,633
10 Day Avg. Volume2,102,853
30 Day Avg. Volume1,180,906
Financial Highlights & Ratios
PEG Ratio-0.16
Price to Book (P/B)1.21
Price to Sales (P/S)0.00
P/FCF Ratio-5.70
Enterprise Value/Market Cap1.22
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-5.82
Forecast
1Y Price Target
$22.14Price Target Upside30.10% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-1.71
Revenue Forecast (FY)$5.00M
Bulls Say, Bears Say
Bulls Say
Low LeverageThe low debt burden gives Contineum greater financial flexibility than a heavily leveraged development-stage biotech. With debt modest relative to equity, the company has more capacity to fund research and operations while limiting interest and refinancing pressures over the next several quarters.
Positive Capital BaseA substantial positive equity base and asset position provide a foundation for continued clinical development. This capitalization can help sustain operations and preserve strategic options while the company works to advance its pipeline, despite current losses and the absence of commercial revenue.
Clinical TolerabilityThe absence of new safety signals is a constructive attribute for a clinical-stage asset, even though efficacy was insufficient on the primary endpoint. Continued tolerability may support review of exploratory data and inform whether the program has a viable role in future development decisions.
Bears Say
No Recurring RevenueThe company currently lacks recurring commercial revenue and remains dependent on research outcomes and future financing or partnering activity. Persistent operating and net losses reduce financial self-sufficiency and make long-term value creation highly dependent on successful clinical development.
Accelerating Cash BurnIncreasing cash consumption raises the resources required to maintain research and clinical programs. Continued negative operating and free cash flow can shorten the period of financial flexibility and may constrain development priorities unless losses decline or additional capital becomes available.
Phase 2 Efficacy FailureMissing the primary endpoint weakens the near-term clinical case for PIPE-307 in major depressive disorder and increases uncertainty around the program’s development path. Although exploratory analyses remain, the result can reduce pipeline productivity and delay any route toward product revenue.
Contineum Therapeutics, Inc. Class A News
CTNM FAQ
What was Contineum Therapeutics, Inc. Class A’s price range in the past 12 months?
Contineum Therapeutics, Inc. Class A lowest stock price was $6.72 and its highest was $17.79 in the past 12 months.
What is Contineum Therapeutics, Inc. Class A’s market cap?
Contineum Therapeutics, Inc. Class A’s market cap is $314.14M.
When is Contineum Therapeutics, Inc. Class A’s upcoming earnings report date?
Contineum Therapeutics, Inc. Class A’s upcoming earnings report date is Nov 11, 2026 which is in 19 days.
How were Contineum Therapeutics, Inc. Class A’s earnings last quarter?
Contineum Therapeutics, Inc. Class A released its earnings results on Jul 30, 2026. The company reported -$0.4 earnings per share for the quarter, beating the consensus estimate of -$0.449 by $0.049.
Is Contineum Therapeutics, Inc. Class A overvalued?
According to Wall Street analysts Contineum Therapeutics, Inc. Class A’s price is currently Undervalued.
Does Contineum Therapeutics, Inc. Class A pay dividends?
Contineum Therapeutics, Inc. Class A does not currently pay dividends.
What is Contineum Therapeutics, Inc. Class A’s EPS estimate?
Contineum Therapeutics, Inc. Class A’s EPS estimate is -0.45.
How many shares outstanding does Contineum Therapeutics, Inc. Class A have?
Contineum Therapeutics, Inc. Class A has 32,958,633 shares outstanding.
What happened to Contineum Therapeutics, Inc. Class A’s price movement after its last earnings report?
Contineum Therapeutics, Inc. Class A reported an EPS of -$0.4 in its last earnings report, beating expectations of -$0.449. Following the earnings report the stock price went down -1.651%.
Which hedge fund is a major shareholder of Contineum Therapeutics, Inc. Class A?
Currently, no hedge funds are holding shares in CTNM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Contineum Therapeutics, Inc. Class A Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.14 (30.10% Upside)
$22.14 (30.10% Upside)
Blogger Sentiment
Bullish
CTNM Sentiment 100%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 2.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 1.0%
Last 30 Days ▲ 1.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-23.88%
12-Months-Change
Fundamentals
Return on Equity
-24.73%
Trailing 12-Months
Asset Growth
36.90%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Contineum Therapeutics, Inc. Class A
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.
CTNM Stock 12 Month Forecast
Average Price Target
$22.14
▲(30.10% Upside)
Technical Analysis
Tvardi Therapeutics
―
Capricor Therapeutics
―
Alpha Tau
―
Immuneering
―
enGene Holdings
―
Ownership Overview
0.52% Insiders
8.92% Mutual Funds
1.94% Other Institutional Investors
77.45% Public Companies and
Individual Investors